ArticleGut pathogens2025
Salmonella typhimurium downregulates circHIPK2 expression via CeRNA mechanism to inhibit cell migration and tumorigenesis.
Article in Gut pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundSalmonella typhimurium (S. typhimurium) is one of the typical intestinal pathogens leading to gastrointestinal diseases. Circular RNA (circRNA) is a covalently closed-loop RNA molecule that lacks 3' and 5' ends, and it plays a crucial role in the pathogenesis and progression of human diseases. However, whether host circRNAs expression could be regulated by S. typhimurium infection during tumorigenesis and development is still not clear. This study aim is to explore the therapeutic potential and underlying mechanisms of altered circular RNAs expression in S. typhimurium infection in colorectal cancer (CRC).
resultsTranscriptomic analysis revealed numerous cellular circRNAs that were significantly regulated by S. typhimurium in the colorectal cancer cell line HCT116. Notably, circHIPK2 exhibited the most pronounced downregulation among them. Knockdown of circHIPK2 inhibited cell motility, tumor growth and epithelial cell cytokine expression like IL8, IL6 and GM-CSF induced by SL1344. The interaction between circHIPK2 with miR-124-3p was confirmed through RNA molecular binding experiment. Furthermore, overexpressed miR-124-3p abrogated cell motility induced by circHIPK2.
conclusionThe S. typhimurium-regulated circHIPK2/miR-124-3p axis is pivotal in CRC pathogenesis and holds promise as a molecular therapeutic target for treating colitis-associated colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.